


# NTM Australian Research Network



## EVENT PROGRAM

Thursday 3<sup>rd</sup> to Saturday 5<sup>th</sup> November, 2022

Mayne Events, UQ Medical School, Herston, Brisbane, QLD



This event is proudly sponsored by

- GOLD SPONSOR - [Insmed](#)
- SILVER SPONSOR - [Beyond Air](#)
- BRONZE SPONSOR - [Pfizer](#)
- BRONZE SPONSOR - [Air Liquide](#)
- BRONZE SPONSOR – [Thermo Fisher](#)
- PATIENT DAY SPONSOR - [Lung Foundation](#)

Gallipoli Medical Research Foundation  
is supported by

 **Greenslopes  
Private Hospital**  
Part of Ramsay Health Care

# NTM Forum Organising Committee

## Professor Rachel Thomson

### Respiratory Research Unit Head

Professor Rachel Thomson is a Thoracic Physician and clinical researcher working at Greenslopes Private Hospital and the Gallipoli Medical Research Foundation. Prof Thomson has an international reputation for her research into lung disease due to NTM. She is at the forefront of research and treatment of patients with NTM infection.



## Dr Andrew Burke

Dr Andrew Burke is a respiratory and infectious diseases physician based at The Prince Charles Hospital and current PhD student. He is investigating ways to improve the administration of antibiotics for patients with NTM disease through dose optimisation and the investigation of novel therapies.



## Organising Committee

- › Dr Felicia Goh
- › Dr Michael Holt
- › Dr Geoff Eather
- › Dr Tim Baird
- › Dr Alice Sawka
- › Prof Scott Bell
- › Dr Malcolm Wilson
- › Prof Claire Wainwright
- › Dr Celine Goffinet

More details and the latest version of the program can be found on the [website](#).

[REGISTER TODAY](#)

Contact [hello.gmrf@ramsayhealth.com.au](mailto:hello.gmrf@ramsayhealth.com.au) for more information.

# Invited Speakers



## **Louis Chai, MBBS, MRCP, PhD.**

**Assistant Professor, Department of Medicine, National University of Singapore**

Dr. Louis Chai is Senior Consultant Infectious Diseases Physician and Associate Professor in the University Medicine Cluster, NUHS, Singapore, as well as Principal Investigator, Opportunistic Infections Group, Division of Infectious Diseases, NUHS. Dr Chai's interests lie in opportunistic and atypical infections in immunocompromised hosts, patients with altered immunity and host-pathogen interaction. He remains deeply entrenched at the bedside in providing clinical service for general infectious diseases. Dr Chai is funded by the National Medical Research Council of Singapore and the National University Health System, Singapore.



## **Ka Lip Chew, MBBS, FRCPath, FRCPA**

**Consultant, Department of Laboratory Medicine, National University Hospital, Singapore**

Dr Ka Lip Chew is a consultant microbiologist at the Department of Laboratory Medicine, NUH. After completing his undergraduate medical degree at the University of Melbourne in 2010, he completed his specialist training in medical microbiology in 2018 at the National University of Hospital. He provides clinical support across diagnostic bacteriology, mycology, and mycobacteriology services.



## **Ieuan Evans, MRCP, PhD**

**Specialist Trainee in Respiratory Medicine, Royal Papworth Hospital, UK**

Ieuan Evans is a specialist in Respiratory Medicine in the East of England with an interest in Cystic Fibrosis, NTM-PD and complex lung infection. He completed a fellowship at the Centre of Complex Lung Infection (CCLI), Royal Papworth Hospital, UK between 2017-2020. He obtained his PhD in Medicine from the University of Cambridge titled 'Developing novel therapies for *M. abscessus*' in August 2021. Research from the PhD has led to the launch of Phase II clinical trial of RESP301 (nebulised nitric oxide generating solution) in Cystic Fibrosis patients with chronic *M. abscessus* infection which is currently running in the Royal Papworth Hospital.

# Invited Speakers



## **Elisa Ignatius, BA, MD, MSc**

**Assistant Professor of Infectious Diseases and Clinical Pharmacology, Johns Hopkins University School of Medicine, USA**

Dr. Elisa H. Ignatius received her B.A. from Columbia University, her M.D. from Emory University, and an MSc from the London School of Hygiene and Tropical Medicine. She completed residency at Emory University and fellowships in both Infectious Diseases and Clinical Pharmacology at Johns Hopkins. She is board certified in Internal Medicine, subspecialty board certified in Infectious Diseases, and serves as an attending Infectious Diseases physician at the Johns Hopkins Hospital and the Johns Hopkins Bayview Medical Center. She is the Program Director for the Johns Hopkins Center for NTM and Bronchiectasis and is an expert in the care of patients with NTM infections, as well as TB, bronchiectasis, HIV/AIDS, and other general infectious diseases. She is the recipient of the Johns Hopkins Clinician Scientist Award, the CHEST Foundation Research Grant in NTM, and an NIH K23 mentored career award for her project entitled "Optimizing Antimycobacterial Therapy Using A Pharmacology-based Approach." Her research interests focus on treatment optimization strategies for mycobacterial infections, including regimens of novel and standard drugs.



## **Katherine Lee, PhD**

**Group Leader and Senior Principal Research Fellow, Murdoch Children's Research Institute, Melbourne, Australia**

Katherine (Kate) Lee is a professor of biostatistics at the Murdoch Children's Research Institute where she is Co-Director of the Clinical Epidemiology and Biostatistics Unit and Associate Director: Biostatistics of the Melbourne Children's Trials Centre. She also holds an honorary appointment at the University of Melbourne, is a lead investigator of the Australian Trials Methodology (AusTriM) Research Network and co-chair of the Australian Clinical Trials Alliance Statistics in Trials Interest Group (ACTA-STInG). She has a BSc in Mathematics, and MSc and PhD in biostatistics (University of Cambridge, 2005). Her biostatistical research interests are in the method of multiple imputation for dealing with missing data and adaptive platform trials.



## **Lex Leong, PhD, MASM, FFSc (RCPA)**

**Senior Medical Scientist, SA Pathology, Adelaide, Australia**

Dr Lex Leong is a clinical scientist leading a team of microbiologists and bioinformaticians within the SA Pathology's Public Health and Epidemiology Laboratory. His work is focused on the translation of pathogen genomics into clinical and public health microbiology for South Australia, and these including the genomic examination of local *M. tuberculosis* and SARS-CoV-2 to reveal true levels of genetic diversity, antimicrobial resistance characterisation to aid in infection control measures, and the clade-level identification of pathogens using genomics approach. Lex is also a national leader in the integration of pathogen genomics into public health surveillance and provides expert guidance in strategic decision and national standardisation as part of his executive position within the Communicable Disease Genomics Network.



# Invited Speakers



## **Kozo Morimoto, MD, PhD**

**Chief, Division of Clinical Research, Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan**

Dr. Morimoto leads the Clinical Research Division project, including designing and analyzing epidemiology and clinical studies of pulmonary disease focusing on NTMPD and bronchiectasis. He has published more than 90 articles in international peer-reviewed journals and four book chapters on NTMPD. He is a member of the International Relation Committee of the Japanese Respiratory Society (JRS) and the Nontuberculous Mycobacteriosis Control Committee of the Japanese society for TB and NTM.



## **Ho Namkoong, MD, PhD, MPH**

**Assistant Professor, Department of Infectious Diseases, Keio University School of Medicine, Japan**

Ho Namkoong is a pulmonary and ID physician at Keio University Hospital in Tokyo, Japan. He completed MPH at Johns Hopkins Bloomberg School of Public Health, and also did his post-doctoral training at NIAID/NIH. He is interested in host factors for pulmonary infectious disease, with a current focus on an international meta-GWAS of NTM-LD. Recently he reported host susceptibility genes for MAC-LD (Namkoong, et al. *Eur Respir J.* 2021) and COVID-19 (Namkoong, et al. *Nature.* in press).



## **Daniel O'Brien, MBBS, FRACP, DMedSc, Dip Anat.**

**Director, Department of Infectious Diseases, The Geelong Hospital, Geelong, Australia.**

Associate Professor Daniel O'Brien is an Infectious Diseases Specialist. He completed his medical degree in 1990 at Melbourne University, and his Infectious Diseases in 1999 following training at the Royal Melbourne and Royal Darwin Hospitals. Currently he is the Director of the Department of Infectious Diseases at The Geelong Hospital, is the Deputy Director of the Barwon South-West Public Health Unit and is a Clinical Associate Professor in the Victorian Infectious Diseases Service and Department of Medicine (University of Melbourne) at The Royal Melbourne Hospital, Australia. His main interests are International Health, especially Buruli ulcer, Tuberculosis, HIV/AIDS and leprosy in resource-limited settings, COVID-19 and Travel Medicine and Immigrant/refugee health. He is currently a member of the World Health Organisation technical working group for the drug treatment of Buruli ulcer. Over more than 25 years he has worked with health programmes in more than 30 resource-limited countries worldwide.



## **Jim Stewart, BSc(Hons), MBBS, FRACP, FRCPA**

**Infectious Diseases Physician and Clinical Microbiologist, Cairns Hospital, Australia.**

Jim is a staff specialist at Cairns Hospital. He completed his training in Infectious Diseases and Clinical Microbiology at Cairns, Princess Alexandra, Monash and Alfred hospitals. His pre-medical research focused on Leishmaniasis and prion disease, subsequent research interests include tropical infections, particularly Melioidosis, Staphylococcus aureus bacteraemia, bacterial genomics, and more broadly the application of quality assurance principles into clinical practice.

# NTM Symposium 2022 Program

Thursday 3 November

Time	Event	Speaker
8:00am – 8:30am: Registration		
8:30am	Welcome and Patient Perspective	TBA
8:45am	Natural history of NTM infections	Alice Sawka
9:15am	Radiology of NTM lung disease	Taryn Reddy
9:30am	Laboratory essentials for the clinician	Ella Meumann
9:45am	Host susceptibility to NTM-Pulmonary Disease	Michael Holt
10:15am – 10:45am: Morning Tea		
10:45am	Environmental exposures and prevention	Rachel Thomson
11:15am	Management of <i>M. avium complex</i> infections	Malcolm Wilson
11:45am	Case discussions: MAC	Panel (TBA)
12:30pm – 1:30pm: Lunch		
1:30pm	Case based management of extrapulmonary NTM	Jim Stewart
2:00pm	Approach to less common NTM	Tim Baird
2:30pm	NTM in Cystic Fibrosis	Lucy Burr
3:00pm – 3:30pm: Afternoon tea		
3:30pm	Management of <i>M. abscessus</i> infection	Andrew Burke
4:00pm	Case based discussion 2 cases: MABS in CF (Paediatric), MABS/mixed infection (adult)	Panel (TBA)
5:00pm: Networking drinks		
6:00pm – 8:30pm: NTM Health Professionals and Researchers Dinner <i>To be held at conference venue</i>		

## Friday 4 November

Time	Event	Speaker
<b>8:00am – 8:20am: Registration</b>		
8:20am	Welcome	
<b>Epidemiology</b>		
8:30am	NTM distribution in the Japanese home and natural environment	Kozo Morimoto
8:50am	NTM in Australians with cystic fibrosis (CF): A national survey	Christine Duplancic
9:00am	Atypical mycobacterium in Victoria 2011-2020	Emma Tippet
<b>Host susceptibility</b>		
9:10am	Genome-wide association study in patients with pulmonary MAC disease	Ho Namkoong
9:30am	Novel Host Factors in Mycobacteria Infections	Louis Chai
9:50am	Impaired ability of macrophages from cystic fibrosis in killing <i>M. abscessus</i>	Abdullah Tarique
10:00am	Endocrine and Body Composition Characteristics of Postmenopausal Women with NTM-PD	Michael Holt
<b>10:10am – 10:40am: Morning Tea &amp; Poster Viewing (#1 – 5)</b>		
<b>Environmental</b>		
10:40am	<b>Title TBA</b>	Dan O'Brien
11:00am	Assessing the efficacy of disinfectants on planktonic cells and biofilms of <i>M. abscessus</i>	Casey Huang
11:10am	Mycobacteria acquisition from potable water (MAP) study: home water collections	Kay Ramsay
<b>Microbiology</b>		
11:20am	<i>In vitro</i> susceptibility of <i>M. abscessus</i>	Ka Lip Chew
11:40am	Implementation of whole genome sequencing for <i>M. abscessus</i> for subtyping and antimicrobial resistance characterisation	Lex Leong
12:00pm	Laboratory evolution of antimicrobial resistance in a <i>M. abscessus</i> isolate from Brisbane's municipal water	Kirby Fahy
12:10pm	Ongoing challenges of <i>Mycobacterium</i> species identification – recent case examples from the Queensland Mycobacterium Reference Laboratory	Melanie Syrmis

Time	Event	Speaker
12:20pm	Antimicrobial susceptibility testing for <i>M. kansasii</i> complex	Chris Coulter
12:30pm – 1:30pm: Lunch & Poster Viewing (#6 – 10) <i>Note: Poster Viewing will be from 1:00pm to 1:30pm for presenters</i>		
Drug Development Pathway		
1:30pm	<i>Sponsor: Beyond Air</i>	
1:40pm	Innovative trial design	Kate Lee
2:00pm	Developing therapies for NTM	Elisa Ignatius
2:20pm	Prevalence of linezolid toxicity in patients with NTM: Sub-analysis of LIMMIT1 study (Linezolid Monitoring to Minimise Toxicity)	Cindy Lau
2:30pm	Conjugated Oligoelectrolytes – A novel antibiotic platform with activity against NTM	Kaixi Zhang
2:40pm	<i>Sponsor</i>	
3:00pm – 3:30pm: Afternoon Tea & Poster Viewing (#11 – 15)		
Treatment		
3:30pm	Novel therapies for <i>M. abscessus</i>	Ieuan Evans
3:50pm	Recent and currently recruiting trials and assessing patient outcomes in clinical trials	Rachel Thomson
4:20pm	Experimental Design for a MAC Observational Study (MACOS)	Ruad Perera
4:30pm	Panel discussion Q&A	Panel (TBA)



## Saturday 5 November

Time	Event	Speaker
<b>8:30am – 8:45am: Registration</b>		
8:45am	Welcome	
9:00am	To treat or not to treat?	Justine Gibson
9:20am	Physiotherapy Management 101 of NTM Bronchiectasis	Kathleen Hall, Libby Yap
10:00am	<i>Sponsor: Air Liquide</i>	
10:10am	Nutritional Complications of NTM	Felicity Loel
<b>10:30am – 11:00am: Morning Tea</b>		
11:00am	Reducing exposure and reinfection	Rachel Thomson
11:20am	Drug toxicity and adverse reactions	Kim Ta
11:40am	Should I enrol in a clinical trial?	Kym Duffield
11:50am	Current clinical trials	Andrew Burke
12:00pm	Coping with chronic illness	Honnie Gorry
<b>12:30pm -1:30pm: Lunch &amp; Anonymous Question Submission</b>		
1:30pm – 2:30pm	Q&A Panel	Andrew Burke Geoff Eather Alice Sawka Rachel Thomson Libby Yap

## Poster Abstracts

#	Title	Author
1	The isolation of environmental <i>Mycobacterium</i> species from soil and household dust in Queensland	Robyn Carter
2	NTM screening in people with cystic fibrosis (pwCF) living in Queensland (QLD): 2015-2021	Christine Duplancic
3	The Nontuberculous Mycobacterial Disease Biobank	Felicia Goh
4	Whole genome analysis of <i>M. abscessus</i> from respiratory and non-respiratory infections within Queensland	Kimberley Smith
5	Culture-based methodologies for the isolation of NTM from water samples	Kay Ramsay
6	Understanding the genomics of <i>M. intracellulare</i> in Queensland	Robyn Carter
7	NTM in Australians with cystic fibrosis (CF): study protocol for a longitudinal cohort observational study	Christine Duplancic
8	Antimicrobial susceptibility of <i>M. abscessus</i> water isolates	Kirby Fahy
9	Phage therapy against NTM, a future novel treatment in sight	Lyman Ngiam
10	In Vitro Susceptibility Testing of Imipenem- Relebactam and Tedizolid against <i>M. abscessus</i> isolates in patients with and without cystic fibrosis	Andrew Burke
11	Clofazimine Enteropathy – A description of two local cases	Céline Goffinet
12	NTM bone and joint infection – a case series	Cameron Holscher
13	Case report: Disseminated NTM disease in children	Holly Jordan
14	Musculoskeletal NTM infections in a tertiary hospital and literature review	Katy Lai
15	Five-year retrospective clinical audit of clofazimine safety and tolerability within Metro South Health	Adrian Watt